Results 201 to 210 of about 326,864 (305)

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025.

JAMA Netw Open
Liu T, Ross JS, Morten CJ, Ramachandran R.   +3 more
europepmc   +1 more source

The regulatory and scientific context in the study of the medicinal use of cannabis in Peru. [PDF]

Front Med (Lausanne)
Wong-Salgado P, Moya-Salazar J, Contreras-Pulache H, Pardo-Villarroel C.   +3 more
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

No fault vaccine injury compensation after COVID-19: A systematic literature review and proposed typology. [PDF]

Hum Vaccin Immunother
Halabi S, Arora N, Durran A, Qian Q, Ummer S, Ginsbach K, Aneja K.   +6 more
europepmc   +1 more source

Identification of major congenital malformations based on healthcare databases in France: A proof‐of‐concept study using the epi‐meres nationwide mother–child register

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Besides registries, healthcare databases can provide useful information for assessing the frequency of major congenital malformations (MCMs) and investigating their risk factors, particularly medication exposures. This study aimed to assess the validity of MCMs identification based on French national, comprehensive healthcare databases ...
Tom Duchemin, Lise Marty, Jérôme Drouin, Sara Miranda, Jérémie Botton, Valérie Olié, Alain Weill, Rosemary Dray‐Spira   +7 more
wiley   +1 more source

Geographical access to community pharmacies in British Columbia, Canada. [PDF]

J Pharm Policy Pract
Tam ACT, Tseng LO, Zhang W.
europepmc   +1 more source

PHARMACEUTICAL PRODUCT HOPPING: IS THERE A ROLE FOR ANTITRUST SCRUTINY? [PDF]

, 2019
Dickey, Bret, Huang, Kun, Rubinfeld, Daniel L   +2 more
core  

On the Prediction of pDNA Productivity Across Diverse Bioprocesses Using Ensemble Hybrid Models

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The global demand for plasmid DNA (pDNA) is rapidly increasing due to its key role in the manufacture of mRNA vaccines and advanced therapy medicinal products (ATMPs). However, the reliance on suboptimal batch and/or fed‐batch processes, as well as the diversity and increasing complexity of plasmid constructs pose significant challenges during
Nikolaos Stratis, Massimo Morbidelli, Alexandros Kiparissides   +2 more
wiley   +1 more source